A Phase 3, Open-Label, Randomized, Multi-Center Study to Assess the Safety & Tolerability of an Induction, Titration, and Maintenance Dose Regimen of BMN 165 Self Administered by Adults With PKU Not Previously Treated With BMN 165

Trial Profile

A Phase 3, Open-Label, Randomized, Multi-Center Study to Assess the Safety & Tolerability of an Induction, Titration, and Maintenance Dose Regimen of BMN 165 Self Administered by Adults With PKU Not Previously Treated With BMN 165

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Pegvaliase (Primary)
  • Indications Phenylketonuria
  • Focus Adverse reactions
  • Acronyms PRISM-1; Prism301
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 21 Mar 2016 According to a BioMarin media release, the company intends to submit a marketing application by the end of 2016 subject to further discussions with the FDA. The results from this study will be presented at the Society of Inherited Metabolic Disorders in April of 2016.
    • 21 Mar 2016 Results from long-term evaluation of this trial published in a BioMarin media release.
    • 25 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top